Multiple Myeloma Hub

48 Episodes

1. How to select maintenance therapies post-ASCT for patients with high-risk MM?

   Published: 9/18/2023
2. Should risk-adapted MM treatment be informed by age or frailty status?

   Published: 9/12/2023
3. How is the immune reconstitution in patients who stop therapy after achieving MRD negativity?

   Published: 2/9/2023
4. What are the main discrepancies between MM treating centers in Brazil?

   Published: 2/6/2023
5. What are the initial data of dara-CyBorD in patients with extramedullary disease?

   Published: 2/3/2023
6. Which patients might benefit the most from isatuximab-based combinations in the relapsed setting?

   Published: 10/2/2022
7. Integrating BCMA-directed agents in the treatment landscape for relapsed/refractory MM

   Published: 8/5/2022
8. The role of consolidation after autologous stem cell transplantation

   Published: 8/5/2022
9. What are the pros and cons of bispecific antibodies for multiple myeloma?

   Published: 7/25/2022
10. Combining bispecific antibodies with monoclonal antibodies to treat relapsed/refractory MM

    Published: 4/21/2022
11. Daratumumab as maintenance therapy for transplant-eligible patients with NDMM: What have we learned from GRIFFIN and CASSIOPEIA trials?

    Published: 1/14/2022
12. Managing infections with novel immunotherapies: Prevention, treatment, and impact on the QoL of patients with MM

    Published: 11/9/2021
13. Should 'cure' be the goal for multiple myeloma?

    Published: 10/14/2021
14. Treating elderly and frail patients with MM: Cure versus disease control

    Published: 10/7/2021
15. Is transplantation still relevant? If yes, in what context?

    Published: 9/30/2021
16. The challenges of monitoring organ response in AL amyloidosis: What has been achieved so far?

    Published: 9/24/2021
17. Is the treatment of high-risk SMM the way for achieving the cure?

    Published: 9/23/2021
18. Does 'cure' have a different meaning in MM?

    Published: 9/15/2021
19. How to treat first relapse in lenalidomide-refractory MM?

    Published: 7/19/2021
20. With the unprecedented results seen with novel therapies, what is needed to overcome the poor prognosis of high-risk MM?

    Published: 6/30/2021